Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Sherlock joins the Kennedy Institute to lead a new research group examining the immunobiology of spondyloarthropathy

The Kennedy Institute would like to welcome Dr Jonathan Sherlock, who joins the Institute as a Senior Clinical Research Fellow funded by the Kennedy Trust for Rheumatology Research. Jonathan leads a new research group that will investigate the immunobiology of human spondyloarthropathy. 

Patients with ankylosing spondylitis or other spondyloarthropathies experience joint pain and stiffness. These symptoms are caused by inflammation and abnormal bone growth in the junctions where bones meet tendons called entheses.

Jonathan’s research will examine the molecular and cellular biology of spondyloarthropathy, with a focus on the role of inflammatory cytokines in driving disease. Current treatments for spondyloarthropathies target inflammation, but are not particularly effective at preventing abnormal bone growth. Jonathan’s studies will provide insight into disease pathogenesis, hopefully leading to better treatment options.

Jonathan will collaborate closely with Oxford Investigators Prof Paul Bowness, Prof Fiona Powrie and Prof Peter Taylor, as well as Prof Christopher Buckley (University of Birmingham).  Analysis of patient tissue samples will provide key component of these investigations.

Prior to joining the Kennedy Institute, Jonathan trained with Prof Christopher Buckley and Dr Daniel Cua (Merck Research Laboratories). His research identified a population of the immune cells in the enthesis that drive pathology in a disease model of spondyloarthropathy.

We wish Jonathan all the best in his new position.

Similar stories

The Kennedy Institute Student Symposium returns for its 5th year

A two-day student symposium returned to the Kennedy Institute bringing together students and peers from across the department to discuss their latest research.

Researchers from the Kennedy Institute awarded MRC funding

Tonia Vincent, Jelena Bezbradica and Alex Clarke have been awarded funding grants by the Medical Research Council (MRC) for different projects.

The Kennedy Institute completes its roof extension

Building work at the Kennedy Institute of Rheumatology has finished, providing a new third floor that houses additional meeting and collaboration space for data science and offices for the management of clinical trials.

Major ERC funding awarded to Professor Michael Dustin

Professor Michael Dustin and an international team of collaborators have been awarded a €10M grant from the European Research Council (ERC) to develop a new biotechnology around supramolecular attack particles (SMAPs) engineered to kill cancer cells.

Drug may boost vaccine responses in older adults

A preliminary study shows that a drug which helps immune cells self-clean may improve vaccine protection in older adults

£3M invested to drive forward early translation through five new Oxford-Bristol Myers Squibb Fellowships

Five new Oxford-Bristol Myers Squibb Fellowships representing an investment of £3M have been announced. The fellowships (formerly Oxford-Celgene) will support postdoctoral researchers and clinicians across five departments within the Medical Sciences Division and the Mathematical, Physical and Life Sciences Division, providing an opportunity for them to gain exposure to the field of commercial drug discovery and development.